FDA Updates SMA Treatment Dosing - Top-Institutions - MDSpire

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

  • By

  • Kathryn Wighton

  • March 30, 2026

  • 2 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Children's Hospital of Philadelphia
    Children's Hospital of Philadelphia

    Philadelphia, PA

    Key Differentiators

    • Neurology
    • Pediatric Neurology
    • Neuromuscular Disorders

  • #2

    Nationwide Children's Hospital
    Nationwide Children's Hospital

    Columbus, OH

    Key Differentiators

    • Neurology
    • Pediatric Neurology
    • Neuromuscular Disorders

  • #3

    Washington University School of Medicine
    Washington University School of Medicine

    St. Louis, MO

    Key Differentiators

    • Neurology
    • Neuromuscular Disorders
    • Genetics

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Neuromuscular Disorders
    • Pediatric Neurology

Original Source(s)

FDA Updates SMA Treatment Dosing

  • by Kathryn Wighton

  • March 30, 2026

Related Content

Factors Influencing Poor Communication Function in Children with Cerebral Palsy: A Multivariate Analysis

Case Report: Pediatric MOG/NMDAR overlap syndrome with delayed cortical MRI evolution and incidental venous sinus hypoplasia

Neurodevelopmental regression Due to PLA2G6-associated neurodegeneration despite normal brain MRI: a case report